Associated Papers
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
LRRK2 rare-variant per-domain genetic burden in Parkinson's Disease: association confined to the kinase domain.
Parlar SC et al.
Npj Parkinson's Disease, 2025
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A et al.
Brain : a Journal of Neurology, 2024
Genetic Screening of a Hungarian Cohort with Focal Dystonia Identified Several Novel Putative Pathogenic Gene Variants.
Salamon A et al.
International Journal of Molecular Sciences, 2023
Genetic landscape of Parkinson's disease and related diseases in Luxembourg.
Landoulsi Z et al.
Frontiers in Aging Neuroscience, 2023
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
Kalogeropulou AF et al.
The Biochemical Journal, 2022
Identification of sixteen novel candidate genes for late onset Parkinson's disease.
Gialluisi A et al.
Molecular Neurodegeneration, 2021
Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
Zhao Y et al.
Drugs, 2019
Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E et al.
Advances in Neurobiology, 2017
Defining neurodegeneration on Guam by targeted genomic sequencing.
Steele JC et al.
Annals of Neurology, 2015
Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.
Anfossi M et al.
Journal of Alzheimer's Disease : Jad, 2014
Structural and functional in silico analysis of LRRK2 missense substitutions.
Cardona F et al.
Molecular Biology Reports, 2014
Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe.
Rubio JP et al.
Human Mutation, 2012
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA et al.
The Lancet. Neurology, 2011
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ et al.
The Biochemical Journal, 2010
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Nuytemans K et al.
Human Mutation, 2010
Identification of four novel potentially Parkinson's disease associated LRRK2 variations among Iranian patients.
Shojaee S et al.
Neuroscience Letters, 2009
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
Kumari U et al.
The Febs Journal, 2009
LRRK2 gene variation and its contribution to Parkinson disease.
Paisán-Ruiz C
Human Mutation, 2009
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
Biskup S et al.
Biochimica Et Biophysica Acta, 2009
Parkinson's disease: from monogenic forms to genetic susceptibility factors.
Lesage S et al.
Human Molecular Genetics, 2009
Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls.
Paisán-Ruíz C et al.
Human Mutation, 2008
Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease.
Hedrich K et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2006
The LRRK2 gene in Parkinson's disease: mutation screening in patients from Germany.
Schlitter AM et al.
Journal of Neurology, Neurosurgery, and Psychiatry, 2006